LYMPHATICA MEDTECH SA

Their core work

Lymphatica Medtech is a Swiss medical device SME developing LymphoDrain, a subcutaneous implantable system designed to provide a permanent treatment for chronic lymphedema — a debilitating condition caused by lymphatic system failure. Their work spans the full product development arc from early feasibility through clinical validation and regulatory approval, targeting CE-marking for the European market. They occupy a narrow but high-value niche: a hardware solution to a chronic condition that currently has no curative treatment, only lifelong compression therapy. Their H2020 engagement reflects a structured commercialization path — Phase 1 to validate the concept, Phase 2 to fund clinical trials and certification.

What they specialise in

How they've shifted over time

The Phase 1 project (2017–2018, €50K) carried no recorded keywords, consistent with a feasibility and market study — the standard SME Instrument Phase 1 output of a business plan and go/no-go decision. The Phase 2 project (2019–2023, €1.81M) introduced a precise technical vocabulary: subcutaneous implantable medical device, lymph drainage system, clinical validation, and CE-marking. This is not a pivot but a deliberate deepening — the same product concept moving from proof-of-concept into regulated clinical development. The trajectory shows a company that used EU funding exactly as the SME Instrument intended: de-risk first, then scale.

Lymphatica Medtech is on a commercialization trajectory — if CE-marking was achieved through the 2019–2023 project, their next phase would be market entry, reimbursement negotiation, and scaling manufacturing, likely requiring industrial or distribution partners rather than further R&D funding.

How they like to work

Lymphatica Medtech operated exclusively as a solo coordinator under the SME Instrument, which by design does not require consortium partners. Both projects list zero external partners, meaning all recorded EU work was self-directed. This tells potential collaborators that the company has strong internal leadership capability but no demonstrated history of large-consortium collaboration — they are accustomed to driving their own agenda rather than coordinating diverse partners.

Lymphatica Medtech has no recorded H2020 consortium partners and no cross-country collaboration in the dataset. As a solo SME Instrument applicant, their EU network is self-contained — any external relationships (clinical sites, suppliers, regulatory consultants) would not be visible in CORDIS data.

What sets them apart

Lymphatica Medtech holds a distinctive position as one of very few companies globally pursuing a hardware implant solution for lymphedema — a market dominated by compression garments and manual therapy, not curative devices. Their combination of Swiss medtech engineering standards, EU clinical validation experience, and a clear regulatory pathway (CE-marking) gives them credibility that academic spinouts or early-stage startups in this space typically lack. For consortium builders, they bring disease-specific clinical expertise and regulatory knowledge that is difficult to find elsewhere.

Highlights from their portfolio

• LymphoDrain (Phase 2)
  At €1.81M, this is among the larger SME Instrument Phase 2 grants and represents a full clinical validation and CE-marking programme for a first-of-kind implantable lymphedema device — an unusually ambitious regulatory target for a two-person SME.
• LymphoDrain (Phase 1)
  The Phase 1 feasibility grant (€50K, 2017) confirmed market and technical viability and directly triggered the Phase 2 application — a textbook SME Instrument progression rarely completed in under two years.